The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFiske Regulatory News (FKE)

Share Price Information for Fiske (FKE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 75.00
Bid: 70.00
Ask: 80.00
Change: 0.00 (0.00%)
Spread: 10.00 (14.286%)
Open: 75.00
High: 75.00
Low: 75.00
Prev. Close: 75.00
FKE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results

19 Feb 2021 07:00

RNS Number : 6517P
Fiske PLC
19 February 2021
 

19 February 2021

 

Fiske Plc

('Fiske' or 'the Company')

Interim Results

The Company announces its interim results for the six months ended 30 November 2020.

In accordance with rule 26 of the AIM Rules for Companies this information is also available, under the Investors section, at the Company's website, http://www.fiskeplc.com .

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

For further information please contact:

• Samantha Harrison / Harrison Clarke / Lukas Girzadas, Grant Thornton UK LLP (Nominated Adviser)

(tel: 020 7383 5100)

• James Harrison, Fiske Plc - CEO

(tel: 020 7448 4700)

Chairman's Statement

 

Trading

 

Our results for the half year to 30 November 2020 show a marked improvement on the two prior six month periods.

 

Total revenues of £2.775 million in the six months to November 2020 represent an 11% increase over revenues in the six months to November 2019 and only a 2% decrease on the following six months to May 2020. This was achieved despite the severe drop in market values in the first quarter of 2020. Whilst our commission revenues were up only 5% on the prior year equivalent period, our investment management fees increased by 14%.

 

Total assets under management ('AUM') have increased over the six months, as one would expect in the improving market conditions, and management fees as a percentage of AUM have improved slightly over the equivalent prior period to November 2019.

 

The increase in operating expenses was held to 2% which is plenty enough in the current low-inflation environment, but very modest given the continued investment in our internal controls and management of the regulatory oversight environment.

 

Overall, our operating results for the half year to 30 November 2020 were a continued improvement on the prior periods which have shown declining operating losses: of £237,000 for the half year to November 2019, £123,000 for the (second) half year to May 2020 and now £21,000 in the half year to November 2020.

 

At the pre-tax level, with interest rates dwindling to nil and fortunately for us not being negative in the UK, interest income has all but disappeared. On a more positive note, whilst we did not receive a Euroclear dividend in the six-month period, we do anticipate one within the current financial year.

 

Euroclear

 

We took advantage of an unsolicited offer to acquire some of our shares in Euroclear by releasing 28% of our holding. Euroclear has been a very profitable investment for Fiske: we have now realised a profit of £1.2m and we still retain £3.7m worth of Euroclear shares. The realisation of this profit has further strengthened our balance sheet and capital adequacy position, providing an extra £1.4m of cash.

 

Markets

 

At the beginning of this six-month period, in May, UK markets had started a price recovery from the market collapse in March but were still 17% below levels at the beginning of 2020. In November market prices began a further rally on the back of the US Presidential win for Biden and the positive vaccine news from both Pfizer and Moderna. For the main UK markets, though, prices still remained some 10% lower than at the start of the year. In parallel, international markets being reflected in indices such as the DAX, S&P and Nasdaq have fared much better, and growing client exposure to these markets has been a positive for the year.

 

Outlook

Much attention remains focussed on the path of the pandemic and both the monetary and fiscal responses. Thus, whilst our own operations continue to run smoothly, a very great many companies, not just the obvious retail and leisure businesses, have been badly affected and the economic impact is yet to be widely appreciated. We retain a healthy degree of caution regarding the immediate outlook for markets and will be very mindful of the likely economic impact of the virus as we progress through the year. Nevertheless, we continue to strive for further improvements in our financial results.

 

 

Clive Fiske Harrison

Chairman

18 February 2021

 

Condensed Consolidated Statement of Total Comprehensive Income

for the six months ended 30 November 2020

 

 

 

note

Six months ended

30 November 2020

Unaudited

Six months ended

30 November 2019

Unaudited

Year ended

31 May 2020

Audited

£'000

£'000

£'000

Total Revenue

2

2,775

2,509

5,383

Operating expenses

(2,796)

(2,746)

(5,743)

Operating Loss

(21)

(237)

(360)

Investment revenue

-

27

143

Finance income

-

87

148

Finance costs

(6)

(35)

(58)

Loss on ordinary activities before taxation

(27)

(158)

(127)

Taxation

(1)

-

-

Loss on ordinary activities after taxation

(26)

(158)

(127)

Other comprehensive income/(expense)

Movement in unrealised appreciation of investments

222

(212)

(793)

Deferred tax on movement in unrealised appreciation of investments

 

(37)

 

39

 

187

Net other comprehensive income/(expense)

185

(173)

(606)

Total comprehensive income/loss for the period/year attributable to equity shareholders

 

159

 

(331)

 

(733)

(Loss) / Earnings per ordinary share (pence), excluding other comprehensive income

3

Basic

(0.2p)

(1.4p)

(1.1p)

Diluted

(0.2p)

(1.4p)

(1.1p)

 

All results are from continuing operations and are attributable to equity shareholders of the parent company.

 

Condensed Consolidated Statement of Financial Position

30 November 2020

 

 

 

As at

30 November 2020

Unaudited

As at

30 November 2019

Unaudited

As at

31 May 2020

Audited

£'000

£'000

£'000

Non-current assets

Intangible assets arising on consolidation

1,216

1,379

1,289

Right-of-use assets

14

188

101

Other intangible assets

49

81

65

Property, plant and equipment

37

28

53

Investments held at Fair Value Through Other Comprehensive Income

3,751

5,546

4,962

Total non-current assets

5,067

7,222

6,470

Current assets

Trade and other receivables

3,459

2,667

2,398

Cash and cash equivalents

2,992

1,377

2,239

Total current assets

6,451

4,044

4,637

Current liabilities

Trade and other payables

3,237

2,479

2,924

Short-term lease liabilities

18

207

124

Current tax liabilities

-

-

-

Total current liabilities

3,255

2,686

3,048

Net current assets

3,196

1,358

1,589

Non-current liabilities

Long-term lease liabilities

-

18

-

Deferred tax liabilities

538

759

611

Total non-current liabilities

538

777

611

Net assets

7,725

7,803

7,448

Equity

Share capital

2,939

2,904

2,923

Share premium

2,082

2,029

2,057

Revaluation reserve

2,736

4,030

3,597

Retained earnings

(32)

(1,160)

(1,129)

Shareholders' equity

7,725

7,803

7,448

 

 

Condensed Consolidated Statement of Changes in Equity

 

 

 

 

Share Capital

Share Premium

Revaluation Reserve

Retained Earnings

Total Equity

£'000

£'000

£'000

£'000

£'000

Balance at 31 May 2020

2,923

2,057

3,597

(1,129)

7,448

(Loss) on ordinary activities after taxation

-

-

-

(26)

(26)

Movement in unrealised appreciation of investments

-

-

222

-

222

Deferred tax on movement in unrealised appreciation of investments

-

-

(37)

-

(37)

Total comprehensive income / (expense) for the period

-

-

185

(26)

159

Realised on disposal of available-for-sale investments

-

-

(1,046)

1,122

76

Share based payment transactions

-

-

-

1

1

Issue of ordinary share capital

16

25

-

-

41

Total transactions with owners, recognised directly in equity

16

25

-

1

42

Balance at 30 November 2020

2,939

2,082

2,736

(32)

7,725

 

Balance at 31 May 2019

2,904

2,029

4,203

(1,004)

8,132

(Loss) on ordinary activities after taxation

-

-

-

(158)

(158)

Movement in unrealised appreciation of investments

-

-

(212)

-

(212)

Deferred tax on movement in unrealised appreciation of investments

-

-

39

-

39

Total comprehensive income / (expense) for the period

-

-

(173)

(158)

(331)

Share based payment transactions

-

-

-

2

2

Issue of ordinary share capital

-

-

-

-

-

Total transactions with owners, recognised directly in equity

-

-

-

2

2

Balance at 30 November 2019

2,904

2,029

4,030

(1,160)

7,803

 

Balance at 1 June 2019

2,904

2,029

4,203

(1,004)

8,132

Loss on ordinary activities after taxation

-

-

-

(127)

(127)

Movement in unrealised appreciation of investments

-

-

(793)

-

(793)

Deferred tax on movement in unrealised appreciation of investments

-

-

187

-

187

Total comprehensive income / (expense) for the period

-

-

(606)

(127)

(733)

Share based payment transactions

-

-

-

2

2

Issue of ordinary share capital

19

28

-

-

47

Total transactions with owners, recognised directly in equity

19

28

-

2

49

Balance at 31 May 2020

2,923

2,057

3,597

(1,129)

7,448

 

Condensed Consolidated Statement of Cash Flows

For the six months ended 30 November 2020

 

 

 

Six months ended

30 November 2020

Unaudited

Six months ended

30 November 2019

Unaudited

Year ended

31 May 2020

Audited

£'000

£'000

£'000

Operating (loss)

(21)

(237)

(360)

Amortisation of intangible assets arising on consolidation

74

66

156

Amortisation of other intangible assets

16

16

32

Depreciation of Right-of-use assets

86

86

173

Depreciation of property, plant and equipment

16

10

39

Expenses settled by the issue of shares

1

1

2

Decrease/(increase) in receivables

(1,063)

(280)

(11)

Increase/(decrease) in payables

316

(354)

75

Cash generated from / (used in) operations

(575)

(691)

106

Tax paid

-

-

-

Net cash (used in)/generated from operating activities

(575)

(691)

106

Investing activities

Investment income received

-

27

143

Interest received

-

87

148

Proceeds on disposal of investments held at FVTOCI

1,400

-

5

Purchases of property, plant and equipment

-

(8)

(62)

Purchases of other intangible assets

-

-

-

Net cash (used in)/ generated from investing activities

1,400

106

234

Financing activities

Interest paid

(6)

(15)

(24)

Proceeds from issue of ordinary share capital

40

-

47

Repayment of lease liabilities

(106)

(96)

(197)

Net cash used in financing activities

(72)

(111)

(174)

Net (decrease) / increase in cash and cash equivalents

753

(696)

166

Cash and cash equivalents at beginning of period

2,239

2,073

2,073

Cash and cash equivalents at end of period/year

2,992

1,377

2,239

 

 

Notes to the Interim Financial Statements

1. Basis of preparation

The Condensed Consolidated Interim Financial Statements of Fiske plc and its subsidiaries (the Group) for the six months ended 30 November 2020 have been prepared in accordance with IAS 34 (Interim Financial Reporting), as adopted in the United Kingdom. The accounting policies applied are consistent with those set out in the May 2020 Fiske plc Annual Report and accounts. These Condensed Consolidated Interim Financial Statements do not include all the information required for full annual statements and should be read in conjunction with the May 2020 Annual Report and Accounts.

The Financial Statements of the Group for the year ended 31 May 2020 were prepared in accordance with International Financial Reporting Standards adopted by in the United Kingdom. The statutory Consolidated Financial Statements for Fiske plc in respect of the year ended 31 May 2020 have been reported on by the Company's auditor and delivered to the registrar of companies. The report of the auditor was (i) unqualified, (ii) did not include a reference to any matters to which the auditor drew attention by way of emphasis without qualifying their report, and (iii) did not contain a statement under Section 498 (2) or (3) of the Companies Act 2006.

Under IAS 27 these financial statements are prepared on a consolidated basis where the Group consists of Fiske plc, the parent, and those subsidiaries in which it owns 100% of the voting rights, being Ionian Group Limited, Fiske Nominees Limited, Fieldings Investment Management Limited and VOR Financial Strategy Limited.

 

The directors have a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future. Thus they continue to adopt the going concern basis of accounting in preparing this half-yearly financial report.

There were no new mandatory standards or amendments to existing standards effective in the six-month reporting period to 30 November 2020.

 

2. Revenues

IFRS 8 requires operating segments to be identified on the basis of internal reports about components of the Group that are regularly reviewed by management to allocate resources to the segments and to assess their performance. Following the acquisition of Fieldings Investment Management Limited in August 2017, their staff and operations have been integrated into the management team of Fiske plc. Pursuant to this, the Group continues to identify a single reportable segment, being UK-based financial intermediation. Within this single reportable segment, total revenue comprises:

 

 

Six months ended

30 November 2020

Unaudited

Six months ended

30 November 2019

Unaudited

Year ended

31 May 2020

Audited

£'000

£'000

£'000

Commission receivable

1,295

1,238

2,732

Investment management fees

1,429

1,255

2,615

2,724

2,493

5,347

Other income / (loss)

51

16

36

2,775

2,509

5,383

 

3. Earnings per share

 

 

 

Basic

Diluted

Basic

£'000

£'000

(Loss) on ordinary activities after taxation

(26)

(26)

Adjustment to reflect impact of dilutive share options

-

-

(Loss)

(26)

(26)

Weighted average number of shares (000's)

11,694

11,735

(Loss) per share (pence)

(0.2)

(0.2)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR FLFLTFTITLIL
Date   Source Headline
15th Apr 20244:27 pmRNSDirector Dealing
6th Mar 202411:51 amRNSDirector Dealing
22nd Feb 20241:21 pmRNSDirector Dealing
19th Feb 20244:38 pmRNSDirector Dealing
16th Feb 20242:47 pmRNSDirector Dealing
16th Feb 20247:00 amRNSInterim results
8th Dec 20234:56 pmRNSDirector Dealing
28th Nov 20233:38 pmRNSDirector Dealing
23rd Nov 202312:52 pmRNSResult of AGM and Confirmation of Board Changes
30th Oct 20233:42 pmRNSDirector Dealing
24th Oct 20237:00 amRNSFinal Results, Annual Report and Notice of AGM
22nd Aug 20231:19 pmRNSDirector dealing
6th Jul 20237:00 amRNSDirector Dealing
31st May 20233:27 pmRNSDirector Dealing
4th Apr 202312:38 pmRNSDirector Dealing
3rd Apr 202310:55 amRNSDirector Dealing
3rd Apr 20237:00 amRNSAcquisition of Client Book
2nd Mar 20237:00 amRNSInterim results
29th Nov 20221:58 pmRNSDirector Dealings
24th Nov 20225:31 pmRNSResult of AGM
20th Oct 20227:00 amRNSFinal Results, Annual Report and Notice of AGM
18th Aug 20229:30 amRNSHolding(s) in Company
17th Jun 20224:13 pmRNSDirector Dealing
1st Mar 20227:00 amRNSHalf-year Report
17th Dec 20214:47 pmRNSDirector Dealing
10th Dec 20217:00 amRNSChange to Accounting Year End
30th Nov 20217:00 amRNSChange of Registered Office
25th Oct 202110:56 amRNSResult of AGM
30th Sep 202111:23 amRNSTotal Voting Rights
29th Sep 20215:29 pmRNSDirector Dealing
17th Sep 20211:08 pmRNSDirector Shareholding & Director Dealing
17th Sep 20219:58 amRNSExercise of Share Options and Issue of Equity
14th Sep 20219:44 amRNSFinal Results, Annual Report and Notice of AGM
5th Jul 202112:56 pmRNSHolding(s) in Company
28th May 20214:21 pmRNSDirector Dealings and Director Shareholding Update
20th Apr 20217:00 amRNSDirector Shareholding Disclosure
19th Feb 20217:00 amRNSInterim Results
8th Feb 20215:28 pmRNSForm 8.3 - Marston's PLC
23rd Dec 20202:46 pmRNSResult of AGM
3rd Dec 202010:01 amRNSDirector Dealing
30th Nov 202012:20 pmRNSIssue of Equity
30th Nov 20207:00 amRNSFinal Results, Posting of Report and Notice of AGM
16th Nov 20207:30 amRNSSale of Euroclear shares
12th Nov 202011:31 amRNSSale of Euroclear shares
22nd Sep 20202:41 pmRNSForm 8.3 - Deltic Energy Plc
27th Jul 20203:54 pmRNSForm 8.3 - Deltic Energy Plc
16th Jul 20207:00 amRNSDirector Retirement
8th Apr 20207:00 amRNSCovid-19 and Trading Update
10th Mar 20209:57 amRNSDirector Dealing
26th Feb 20207:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.